

Donald M. Poretz, MD/1

CURRICULUM VITAE

Donald M. Poretz, MD, FACP, FIDSA

Infectious Diseases Physicians, Inc.

Main Office
3289 Woodburn Road, #200
Annandale, VA 22003

Research Office
3289 Woodburn Road, #250
Annandale, VA 22003

Personal:

Born:

Home:

Undergraduate Work:

University of Virginia
Bachelor of Arts, 1962

Graduate Work:

Medical College of Virginia
School of Medicine
MD, 1966

Internship:

Intern in Internal Medicine
Medical College of Virginia, 1966 -1967

Residency:

Resident in Internal Medicine
Medical College of Virginia, 1967 -1968; 1970-1971

Fellowship:

Fellowship in Infectious Diseases
Medical College of Virginia, 1971-1972

Certification:

Diplomate, American Board of Internal Medicine, 1972
Diplomate, Sub-Specialty Board of Infectious Diseases, 1976

Military:

Major, United States Army Medical Corps
106th General Hospital, Japan
249th General Hospital, Japan, 1968-1970

Donald M. Poretz, MD/2

Positions Held:

1972-2001	Chief, Infectious Diseases The Fairfax Hospital Falls Church, Virginia
1973-present	Private Practice of Infectious Diseases Annandale, Virginia
1977-1985	Chairman, Infections Committee The Fairfax Hospital Falls Church, Virginia
1978-1995	Consultant in Infectious Diseases Northern Virginia Training Center Fairfax, Virginia
1983 - 1985	Medical Malpractice Review Panel for state of Virginia
1985-1987	President, Medical Staff The Fairfax Hospital Falls Church, Virginia
1985-present	Clinical Professor, Internal Medicine Georgetown University School of Medicine Washington, DC
1987-1991	Board of Trustees Fairfax Hospital and Fairfax Hospital Systems
1988-1990	Task Force for AIDS Fairfax County School Board Advisory Committee
1990-1996	Medical Director HIV Services INOVA Health Care Systems Fairfax, Virginia
1991-1994	Board of Directors Fairfax Symphony Orchestra
1991-present	Consultant Hospice of Northern Virginia Arlington, VA
1992	Advisor Panel, Hoechst Roussel Pharmaceuticals

Donald M. Poretz, MD/3

1992-1995	Board of Directors Nelson Information Systems
1995-1997	Board of Directors OPIVITA
1995-present	Consultant in Infectious Diseases Northern Virginia Mental Health Institute Falls Church, Virginia
1996	Consultant to Becton Dickinson Diagnostic Instrument Systems
1996	Consultant to Agouron Pharmaceuticals
1996-present	Advisor HIV Services Fairfax, VA
1996-present	Section Editor, Issues in Clinical Practice <i>Inf Dis Clin Prac</i>
1996-present	Consultant to State of Virginia AIDS Drug Assistance Program (ADAP)
1997-2001	Science and Technology Committee, MAMSI
1997	HIV/AIDS Project Advisory Group Capital Care, BCBS of the National Capital Area
1998-2001	Councillor, Infectious Diseases Society of America
2000-present	Consultant to Ortho-McNeil Anti-Infectives Optimistic Future Advisory Board
2002	Board of Directors, Physicians Health Plan of Maryland (MAMSI)

Donald M. Poretz, MD/4

Awards:

1. The Vicennial Medal
For 20 years of service on medical faculty
Georgetown University Medical School
1972-1992
2. Certificate of Service
Medical Staff Executive Committee
The Fairfax Hospital
1979-1989
3. Certificate of Appreciation
For service in elevating the standards and advancing the Science of Oral Surgery
The Middle Atlantic Society of Oral Surgeons
1980
4. "Young Internist of the Year"
Virginia Society of Internal Medicine
February, 1981
5. Certificate of Merit
For leadership as President
Northern Virginia Academy of Internal Medicine
1981-1982
6. Certificate of Recognition
For time, effort, and assistance to the Fairfax Hospital System
Medical Affairs Council
1983 -1989
7. Certificate of Service
For leadership and service as President of the Medical Staff
The Fairfax Hospital
1985-1987
8. Certificate of Appreciation
For service on the Ad Hoc Advisory Committee on AIDS Policies
Fairfax County Public Schools
March 23, 1988
9. Certificate of Service
As a volunteer governing board member
Inova Health Systems
January 1, 1989

Donald M. Poretz, MD/5

10. **Certificate of Recognition**
For outstanding contribution to teaching
Department of Medicine
The Fairfax Hospital
1991
11. **Public Service Award**
In recognition of contribution to the fight against HIV/AIDS in Northern Virginia
Whitman-Walker Clinic of Northern Virginia
1993
12. **Certificate of Appreciation**
For dedicated service as a coordinator for the Clinical Training Program for Health Care Professionals
Northern Virginia HIV Resource and Consultation Center
July 26, 1995
13. **Vernon K. Vance Memorial Award**
For Teaching Excellence
Department of Medicine
The Fairfax Hospital
1995
14. **Iams Memorial Quality Leadership Award**
Inova Health System
2000
15. **Leon G. Smith Infectious Disease Institute Hall of Fame**
Saint Michael's Medical Center
Newark, NJ
2000

**APPEARS THIS WAY
ON ORIGINAL**

Donald M. Poretz, MD/6

Professional Societies:

Fellow, American College of Physicians

1979-1981

Secretary-Treasurer, Virginia Chapter

1979-1983

Governor's Council, Virginia Chapter

Fellow, Infectious Diseases Society of America

1985-1990

Clinical Affairs Committee

1994

Task Force on Health Care Reform

1996-1999

Public Policy Committee

1997

Chairman, Public Policy Committee

10/97

Member, Search Committee to find new Executive Director

1/28/98

Testified on behalf of IDSA before the Subcommittee on

Labor, HSS, and Education, Committee on Appropriations,

U.S. House of Representatives

11/98-2001

Councillor

National Foundation for Infectious Diseases

1981-present

Board of Directors

2002

Vice President

Medical Society of Virginia

1987-present

Chairman, Committee on AIDS

American Society for Microbiology

American Association for the Advancement of Science

Northern Virginia Society of Internal Medicine

1979

Treasurer

1979-1982

Executive Committee

1981-1982

President

American Medical Association

Fairfax County Medical Society

American Society of Internal Medicine

Virginia Society of Internal Medicine

Virginia Infectious Diseases Society

Greater Washington Infectious Diseases Group

Published Articles:

1. Guynn Jr. JB, Poretz DM, Duma RJ. Growth of various bacteria in a variety of intravenous fluids. *Amer J Hosp Pharm* 1973; 30:321-5.
2. Middleton FG, Poretz DM, Duma RJ. Clinical and laboratory evaluation of amoxicillin (BRL 2333) in the treatment of urinary tract infections. *Antimicrob Agents Chemother* 1973; 4:25-30.
3. Miller GB, Duma RJ, Middleton FG, Poretz DM. Use of Amoxicillin in the treatment of urinary tract infections. *J Infect Dis* (Suppl) 1974;129:S237-S240.
4. Poretz DM, Wood L, Park C. Adenocarcinoma of the colon presenting as Clostridium septicum cellulitis of the left thigh. *So Med J* 1974;67:862-4.
5. Poretz DM. The NBT test in bacterial and non-bacterial pharyngitis. *VA Med* 1974;101:653-6.
6. Poretz DM, Guynn JB, Duma RJ, Dalton HP. Microbial contamination of glass bottle (open-vented) and plastic bag (closed-nonvented) intravenous fluid delivery systems. *Amer J Hosp Pharm* 1974;31:726-32.
7. Poretz DM, Smith MN, Park CH. Intracranial suppuration secondary to trauma. Infection with Nocardia asteroides. *JAMA* 1975;232:730-1.
8. Dineen JF, Poretz DM. Chronic meningococcemia. *VA Med* 1975; 102:957-8.
9. Park CH, Poretz DM, Goldenberg RI. Erysipelothrix endocarditis with cutaneous lesion. *So Med J* 1976;69:1101-3.
10. Young DV, Poretz DM. Treatment of Salmonella prostatitis with trimethoprim sulfamethoxazole. *So Med J* 1978;71:742.
11. Poretz DM. Author of three chapters in Textbook of Infectious Diseases (Bennett, Mandell, Douglas) Wiley Medical 1979; two chapters, second edition, 1984.
12. Wilmot BD, Wineland RK, May DF, Poretz DM. Acute pyogenic sacroiliitis. *Clinical Proceedings, Children's Hospital Medical Center* 1980;27-30.
13. Poretz DM. Toxic Shock Syndrome in Virginia. *VA Med* 1981; 108:131.
14. Eron LJ, Huckins C, Park C, Poretz D, Gelman H, Ball M. Mycobacterium chelonae infects the maxillary sinus: a rare case. *VA Med* 1981;108:335-8.
15. Poretz DM. Moxalactam usage in a community hospital. Abstract for 12th International Congress of Chemotherapy 1981.

16. Poretz DM, Eron LJ, Goldenberg RI, Gilbert AF, Rising J, Sparks S, Horn CE. Intravenous antibiotic therapy in an outpatient setting. *J Am Med Assoc* 1982;248(3):336-9.
17. Poretz DM. The private practice of infectious diseases. *J Inf Dis* 1983;147:417-21.
18. Eron LJ, Goldenberg RI, Park CH, Poretz DM. Ceftazidime therapy of serious bacterial infections. *Antimicrob Agents Chemother* 1983;23:236-41.
19. Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. *Antimicrob Agents Chemother* 1983;23:731-7.
20. Eron LJ, Goldenberg RI, Poretz DM, Park CH. Piperacillin therapy for Pseudomonas infections. *So Med J* 1983;76: 859-62.
21. Eron LJ, Hixon DL, Park CH, Goldenberg RI, Poretz DM. Imipenem versus moxalactam in the treatment of serious infections. *Antimicrob Agents Chemother* 1983;24:841-6.
22. Eron LJ, Park CH, Goldenberg RI, Poretz DM. Ceftriaxone therapy of serious bacterial infections. *J Antimicrob Chemother* 1983;12:65-78.
23. Denny L, Eron LJ, Toy C, Goldenberg RI, Poretz DM. Ceftriaxone therapy of osteomyelitis. Current Chemotherapy, American Society for Microbiology, Washington D.C. 1983;18:43-8.
24. Eron LJ, Hixon DL, Park CH, Goldenberg RI, Poretz DM. A new cephalosporin: Ceftriaxone. Ceftriaxone therapy in an outpatient setting. Excerpta Medica, in Progress in Therapy of Bacterial Infections, Amsterdam 1983:123-9.
25. Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftazidime in patients with Pseudomonas infections. *J Antimicrob Chemother* 1983;12(Suppl A):161-9.
26. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. *Am J Surg* 1984;148(4A):1-4.
27. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. *Am J Med* 1984;77(4C):77-83.
28. Goldenberg RI, Poretz DM, Eron LJ, Rising JB, Sparks SB. Intravenous antibiotic therapy in ambulatory pediatric patients. *Ped Infect Dis* 1984;3(6):514-7.
29. Eron LJ, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone parenteral therapy in the outpatient clinic. Serious Infections: Treatment and Prevention, Update Publications, London 1985;189-92.

30. Eron LJ, Poretz DM, Hixon DL, Park CH. Therapy of infections by imipenem. *Fortschritte Antimikrob Chemother* 1985; 266:88-93 .
31. Eron LJ, Harvey L, Hixon DL, Poretz DM. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. *Antimicrob Agents Chemother* 1985;27:308-10.
32. Eron LJ, Goldenberg RI, Poretz DM. Outpatient cefoperazone therapy. Recent Advances in Chemother, ed. by J. Ishigami, University of Tokyo Press, Tokyo 1985;1040-1.
33. Eron LJ, Poretz DM, Goldenberg RI, Rising JB, Sparks S. Treatment of infections in outpatients with cefoperazone. The Efficacy and Safety of Cefoperazone, ed. by W Kirby, Roerig, New York 1986;28-31.
34. Masur et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. *Ann Int Med* 1986; 104:41-4.
35. Poretz DM. Wrote chapter entitled "Combination Office and Home Delivery of Parenteral Antibiotics" in booklet entitled Outpatient Delivery of Parenteral Antibiotic Therapy for symposium in Tucson, AR, October 21-22, 1986.
36. Peereboom D, Poretz DM. Eikenella corrodens cervical osteomyelitis: case report. *VA Med* 1987;114:150-3.
37. Macher A, Bardenstein DS, Zimmerman LE, Steigman CK, Pastore L, Poretz DM, Eron LJ. Pneumocystis carinii choroiditis in a male homosexual with AIDS and disseminated pulmonary and extrapulmonary P. carinii infection. *N Engl J Med* 1987; 316:1092 (Letter to the Editor).
38. Poretz DM. Outpatient intravenous antibiotic therapy. *Outpatient Therapy Med* 1987;2(4):1,12-4.
39. Poretz DM. Home management of intravenous antibiotic therapy. *Bull N Y Acad Med* 1988;64(6):570-6.
40. Poretz DM. Home management of antibiotic therapy, in Current Clinical Topics in Infectious Diseases, J Remington and M Swartz, Blackwell Scientific Publications, 1989;10: 27-42.
41. Payne FJ, Poretz DM, Sharrett, CS. A community program of comprehensive care for HIV disease. Abstract #E.809. Proceedings of the Fifth International Conference on AIDS, June 4-9, 1989, Montreal, Canada.
42. Poretz DM. Clinical considerations of home intravenous therapy. *Medical Interface* 1990;3(11):23-7.

43. Poretz DM. The infusion center: a model for outpatient parenteral antibiotic therapy. *Rev Inf Dis* 1991;13(Suppl 2):S142-6.
44. Poretz DM. Home intravenous antibiotic therapy. *Clinics in Geriatric Medicine* 1991;7(4):749-63.
45. Poretz DM. High tech comes home. (Editorial) *Amer J Med* 1991;91(5):453-4.
46. Poretz DM. Outpatient parenteral therapy, ed. by Sherwood L. Gorbach, John G. Bartlett, Neil R. Blacklow, W. B. Saunders Company, *Inf Dis* 1992, pp. 353-7.
47. Payne FJ, Sharrett CS, Poretz DM, Eron LJ, et al. Community-based case management of HIV disease. *Am J Public Health* 1992;82(6):893-4.
48. Poretz DM. Capitation for AIDS patients. *Inf Dis Clin Prac* 1993;(2)1:72-4.
49. Poretz DM. Infusion Center, Office, and Home. *Hospital Practice* 1993;28(2):40-3.
50. Pons V, Greenspan D, et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. (Part of the multicenter study group.) *J Acquired Immune Deficiency Syndromes* 1993;6:1311-6.
51. Guest Editor, Introduction, *Amer J Med* 1994;97(2A):1-2.
52. Poretz DM. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. *Amer J Med* 1994;97(2A):23-7.
53. Poretz DM. Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: global analysis of a large-scale, multicenter trial. *Amer J Med* 1994;97(2A):34-42.
54. Poretz DM. Outpatient parenteral antibiotic therapy. *Int J Anti Agents* 1995;5:9-12.
55. Poretz DM. Commentary: a decade's experience. (Hindes R, Winkler C, Kane P, et al. Outpatient intravenous antibiotic therapy in Medicare patients: cost-savings analysis.) *IDCP* 1995;4(3):217-8.
56. Poretz DM. Counseling on lifestyles, physical fitness, nutrition, and social responsibility: management of the HIV positive person. A clinical monograph from the National Foundation for Infectious Diseases 1996; page 11.
57. Tice AD, Slama TG, Berman S, Poretz DM, et al. Managed care and the infectious diseases specialist. *Clin Inf Dis* 1996; 23:341-68.

58. Cohen C, Sun E, Poretz D, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients. Abstract for 36th ICAAC & 34th IDSA Annual Meeting, New Orleans, CA, September 1996.
59. Farthing C, Japour A, Cohen C, Cameron W, Poretz D, et al. Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with Ritonavir (RIT)-Saquinavir (SQV) in protease inhibitor naive patients. Abstract for 37th ICAAC & 35th IDSA Annual Meeting, Toronto, Ontario, Canada, September 1997.
60. Poretz DM. Outpatient parenteral therapy, ed. by Sherwood L. Gorbach, John G. Bartlett, Neil R. Blacklow, W. B. Saunders Company, *Inf Dis* 1998, pp. 422-3.
61. Poretz DM. Evolution of outpatient parenteral antibiotic therapy. *Inf Dis Clin N Amer* December 1998; 12(4):827-34.
62. Tice AD, Poretz D, Cook F, et al. Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself. *Clin Inf Dis* 1998; 27:1415-21.
63. Cameron DW, Japour AJ, Poretz DM, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. *AIDS* 1999;13(2):213-24.
64. Poretz DM. OHPAT therapy in the USA. Home Page Home & Outpatient Management Education (newsletter). Issue 7, Spring 1999, pages 1-3.
65. Poretz DM. Editorial Response: Direct Involvement of Physicians is Vital to Outpatient Parenteral Antimicrobial Therapy for Central Nervous System Infections. *Clin Inf Dis* 1999;29:1400-1.
66. Poretz DM. Book review of "1999 Guidelines for Infectious Diseases in Primary Care" by Sherwood L. Gorbach, John B. Bartlett, Matthew Falagas and Davidson H. Hamer. Baltimore: Williams & Wilkins, 1999. 345 pp. \$24..95. August 1999, *Clin Inf Dis* (29)2.
67. Hayden FG, Atmar RL, Schilling M, Johnson DO, Poretz D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med* 1999; 341(18):1336-43.
68. Birx DL, Loomis-Price LD, Aronson N, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. *J Inf Dis* 2000;181:881-9.
69. Poretz DM. Outpatient management of infectious diseases. *IJCP* Dec. 2000;115:23-5.

Conferences and Papers Presented:

1. "Obstetrical infections"
Medical Staff - Metropolitan Hospital for Women, Washington, DC
Fall 1972
2. Monthly Infectious Diseases Conference
Fairfax Hospital, Falls Church, VA
August 1972 - present
3. Lectures and conferences at most of the hospitals in Northern Virginia
August 1972 - present
4. "Clinical evaluation of a new antibiotic: amoxicillin"
W.T. Thompson Day Medical College of Virginia, Richmond, VA
June 1973
5. "Management of hospital infections and related diseases"
Rogers Memorial Hospital, Washington, DC
November 19, 1973
6. Yearly presentation of cases to Washington, DC inter-institutional infectious diseases group
1974 - present
7. "Aeromonas sepsis"
Medical Grand Rounds - Georgetown University School of Medicine,
Washington, DC
April 1974
8. Review course for re-certification by American Board of Internal Medicine
Infectious Diseases Section
September 1974
9. Clinical pathological conference on endocarditis
Georgetown University School of Medicine, Washington, DC
September 1974
10. "Tuberculosis: current concepts"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
November 14, 1974
11. "Antibiotics: current concepts"
National Orthopaedic and Rehabilitation Hospital, Arlington, VA
December 7, 1974

Donald M. Poretz, MD/13

12. "Microbial contamination of I.V. fluids in glass bottles and plastic bags"
Seminar - Loudoun Memorial Hospital, Leesburg, VA
June 28, 1975
13. "Infective endocarditis: a review of 24 cases"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
January 1976
14. "Urinary tract infections"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
April 8, 1976
15. "Antibiotic side effects"
Washington Metropolitan Chapter of Hospital Pharmacists
September 9, 1976
16. "Influenza"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
September 16, 1976
17. "Hepatitis"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
December 6, 1976
18. "Antibiotic therapy"
Medical Staff - Potomac Hospital, Woodbridge, VA
January 20, 1977
19. "Pneumonia in children: diagnosis and medical management"
Pediatric Pulmonary Symposium sponsored by the Potomac Lung Association,
Arlington Hospital, Arlington, VA
March 9, 1977
20. "Common office infectious disease problems"
Northern Virginia Consortium, Alexandria Hospital, Alexandria, VA
March 26, 1977
21. "Antibiotics and their complications for the oral and maxillofacial patient"
Middle Atlantic Society of Oral Surgeons, Baltimore Hilton Inn
April 14, 1977
22. "Infections caused by atypical mycobacteria"
George Washington University Medical Center, H.B.Burns Memorial Building,
Washington, DC
June 1, 1977

Donald M. Poretz, MD/14

23. "Indications for antibiotic use"
Association for Practitioners in Infection Control, Lanham, MD
October 7, 1977
24. "Osteomyelitis"
George Washington University Medical Center, Washington, DC
November 9, 1977
25. "Antibiotics"
Panel - American College of Physicians Regional Meeting, Hot Springs, VA
February 11, 1978
26. "Tuberculosis in gynecological practice"
George Washington University Medical Center, Obstetrical Department,
Washington, DC
April 19, 1978
27. "Pharmacological agents for pneumonia"
Potomac Lung Association, Alexandria Hospital, Alexandria, VA
April 27, 1978
28. "Treatment of anaerobic infections"
Fourth Annual Educational Conference of the Association for Practitioners in I
Infection Control, Alexandria, VA
October 12, 1978
29. "Patient management"
Tuberculosis symposium, Potomac Lung Association,
Alexandria Hospital, Alexandria, VA
November 29, 1978
30. "Diagnosis of surgical infections"
Northern Virginia Consortium for Continuing Medical Education
March 24, 1979
31. "Extrapulmonary mycobacterial diseases"
Washington Metropolitan Area Pulmonary Conference
Georgetown University School of Medicine, Washington, DC
April 4, 1979
32. "Studies of LY127935, a new antibiotic"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
March 11, 1980
33. "Pneumonia"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
April 10, 1980

34. "Antibiotics"
Medical Staff - Loudoun Memorial Hospital, Leesburg, VA
April 18, 1980
35. "New antibiotics"
Southern Obstetrical Society, Alexandria, VA
April 18, 1980
36. "Toxic shock syndrome"
Medical Grand Rounds - George Washington University, Obstetrical Department,
Washington, DC
November 12, 1980
37. "Toxic shock syndrome in Virginia - report of 8 cases"
Virginia Regional Meeting of American College of Physicians, Hot Springs, VA
February 21, 1981
38. Toxic shock syndrome - Diehl Memorial lecture
Lutheran Hospital, Baltimore, MD
April 4, 1981
39. "Newer aspects of venereal diseases"
Combined meeting of Northern Virginia Academies of Pediatricians and
Obstetricians/Gynecologists
May 1981
40. "Experience with a new antibiotic - moxalactam (LY127935) in a community hospital - 87
episodes of infection in 79 patients"
12th International Conference of Chemotherapy, Florence, Italy
July 1981
41. "Private practice of infectious diseases"
Infectious Diseases Society of America, Miami, FL
October 7, 1982
42. "Third generation cephalosporins"
American College of Physicians tri-state meeting, Baltimore, MD
October 10, 1982
43. "Clinical problems in pediatric infectious diseases"
The Fairfax Hospital Regional Pediatric Conference
West Park Hotel, Tyson's Corner, VA
June 8 & 9, 1983
44. "Ceftriaxone therapy of osteomyelitis"
International Congress of Chemotherapy meeting, Vienna, Austria

Donald M. Poretz, MD/16

August 30, 1983

45. "Outpatient intravenous antibiotics"
Medical Staff - Sibley Memorial Hospital, Washington, DC
November 4, 1983
46. "Update on toxic shock syndrome"
Medical Grand Rounds - George Washington University Medical Center,
Obstetrical Department, Washington, DC
November 23, 1983
47. "Outpatient intravenous antibiotics"
Medical Staff - Seventh Day Adventist Hospital, Takoma Park, MD
January 13, 1984
48. "Outpatient intravenous antibiotic therapy"
Symposium - Children's Hospital, St. Paul, MN
January 26, 1984
49. "AIDS"
Workshop - Mid Atlantic Blood Bank Meeting, Baltimore, MD
March 3, 1983
50. "Outpatient antibiotic therapy"
Gettysburg Hospital, Gettysburg, PA
April 11, 1984
51. "Use of home I. V. antibiotic therapy"
Symposium - Memorial Hospital, South Bend, IN
September 12, 1984
52. "Intravenous antibiotic therapy in an outpatient setting"
Poster session presented at ICAAC
Interscience Conference for Antimicrobial Agents and Chemotherapy,
Washington DC
October 9-11, 1984
53. "Outpatient I. V. antibiotics"
Medical Grand Rounds - Wilmington Medical Center, Wilmington, DE
October 30, 1984
54. "New approaches to antibiotic therapy in a cost concerned environment"
American College of Physicians, Maryland Chapter
December 1, 1984
55. "A strategy for reducing length of stay: outpatient care"
Dallas, Texas

December 1, 1984

56. "Antibiotic update"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
January 15, 1985
57. "Outpatient intravenous therapy"
The Year in Internal Medicine
Northwestern University Medical School, Chicago, IL
January 23, 1985
58. "I.V. antibiotics - outpatient management and home therapy"
Update in Infectious Diseases, Medical College of Virginia
September 6, 1985
59. "AIDS"
Medical Staff - St. Elizabeth's Hospital, Washington, DC
December 4, 1985
60. "Update on sexually transmitted diseases"
Northern Virginia Consortium
61. "Intravenous therapy in an outpatient setting"
Symposium - Good Samaritan Hospital and Health Center, Dayton, OH
April 16, 1986
62. "Outpatient intravenous antibiotic therapy"
Fourth Annual West Virginia Conference on Infectious Diseases
The Charleston Marriott, Charleston, WV
May 14, 1986
63. "Management of home antibiotic therapy"
Seminar - Cedars-Sinai Medical Center, Los Angeles, CA
September 6, 1986
64. "What is the impetus to develop home healthcare programs?"
Symposium - Jefferson Medical College of Thomas Jefferson University,
Philadelphia, PA
October 20, 1986
65. "Combination of office delivery and home delivery of parenteral antibiotics using
paramedical personnel such as nurses and pharmacists"
Symposium - The Tucson National Resort and Spa, Tucson, AR
October 21, 1986
66. "Common office infections"
Filipino American Medical Society, Fairfax Hospital, Falls Church, VA

January 23, 1987

67. "Home parenteral drug therapy: technology and patient care"
Yale-New Haven Hospital Physicians and Health Care Professionals, Yale
University School of Medicine
May 27, 1987
68. "The changing pattern of infectious disease practice: an update"
Joint Interscience Conference on Antimicrobial Agents and
Chemotherapy/Infectious Diseases Society of America Symposium, Sheraton
Centre Hotel, The New York Hilton, New York, NY
October 7, 1987
69. "Home management of antibiotic therapy"
SK&F/FSK Anti-infective Conference - Controversies in Infectious Disease,
Laguna Niguel, CA
November 14-16, 1987
70. "Acquired immune deficiency syndrome: a medical overview"
George Mason University, Fairfax, VA
March 17, 1988
71. "Psychological aspects of AIDS: medical aspects and future trends"
Department of Social Work and INOVA Home Care - Fairfax Hospital, Falls
Church, VA
March 25, 1988
72. "Practice of infectious diseases"
Infectious Diseases Fellows preparing for Infectious Diseases boards, NIH,
Bethesda, MD
March 29, 1988
73. AIDS discussion
Annual meeting of Virginia Bar Association, Cavalier Hotel, Virginia Beach, VA
June 17, 1988
74. "Antibiotic update"
Medical Staff - Mary Washington Hospital, Fredericksburg, VA
August 12, 1988
75. "AIDS in Virginia"
Annual meeting of Medical Society of Virginia, Williamsburg, VA
November 4, 1988
76. "Implementing universal precautions"
Moderator of a panel discussion - Third International Conference on AIDS and
Hepatitis B, Washington, DC

Donald M. Poretz, MD/19

November 21, 1988

77. "AIDS and health care workers"
Conference for AIDS and Health Care Workers, Bethesda Hyatt, Bethesda, MD
December 3, 1988
78. "A model program for home intravenous antibiotics"
Symposium on home care sponsored by Roche Laboratories, Snowbird, UT
January 10, 1989
79. "Outpatient management of HIV positive patients"
Symposium on AIDS, Fairfax, VA
April 29, 1989
80. "Medical/epidemiologic overview of HIV infection"
Symposium on AIDS and the Medical Office, Fairfax, VA
May 24, 1989
81. "A community program of comprehensive care for HIV disease"
Fifth International Conference on AIDS Montreal, Quebec, Canada
June 4-9, 1989
82. "Outpatient IV antibiotic therapy"
Fifteenth Annual Educational Conference, Holiday Inn Fair Oaks, Fairfax, VA
September 28, 1989
83. "The AIDS dilemma"
Fairfax County Chamber of Commerce Human Services Program, Fort Belvoir
Officers Club
January 11, 1990
84. "How to manage an outpatient IV antibiotic program"
The Practice of Infectious Diseases - A Practical Symposium for the Infectious
Disease Clinician, sponsored by The Clinical Affairs Committee, Infectious
Diseases Society of America, San Diego, CA
January 19, 1990
85. "Outpatient intravenous antibiotic therapy"
Contemporary Topics in Fever and Antibiotics
10th Annual Infectious Disease/Infectious Control Symposium,
Sheraton Tara Hotel, Springfield, MA
April 4, 1990
86. "Intravenous antibiotic therapy in the elderly"
American Geriatric Society and American Association of Home Care Physicians,
Atlanta, GA
May 17, 1990

Donald M. Poretz, MD/20

87. "Fungal infections"
Group Health Association, Fairfax, VA
October 3, 1990
88. "Update on AIDS"
Department of Medicine, Fairfax Hospital, Falls Church, VA
December 6, 1990
89. "Nosocomial infections in the intensive care unit: managing pulmonary disease and gram-negative sepsis"
Roerig-sponsored symposium, Naples, FL
December 15, 1990
90. "New approaches to antifungal therapy"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
March 12, 1991
91. "Diagnosis and treatment of fungal infections"
Medical Grand Rounds - Montgomery General Hospital, Olney, MD
October 24, 1991
92. "Tick-transmitted diseases"
Northern Virginia Mental Health Institute, Falls Church, VA
November 21, 1991
93. "Outpatient management of the HIV-infected patient"
5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases
Atlanta, GA
March 31, 1992
94. "Educational needs of primary and support care providers"
5th National Forum on AIDS, Hepatitis, and Other Blood-Borne Diseases
Atlanta, GA
March 31, 1992
95. "Home intravenous antibiotic therapy"
Hoechst Pharmaceuticals, Parsippany, NJ
April 7, 1992
96. "Update on AIDS"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
July 28, 1992
97. "Outpatient continuous 24-hour infusion of cefotaxime with a new infusion device"
Infectious Diseases Society of America, Anaheim, CA
October 11, 1992

98. "Isolation of Acanthamoeba spp. from multiple cutaneous lesions of an AIDS patient"
Poster session presented at ICAAC (V. Iyengar, L.G. Hefter, C.H. Park, D.M. Poretz, M.L. Simon, and L. Coleman)
Interscience Conference for Antimicrobial Agents and Chemotherapy, Anaheim, CA
October 11-14, 1992
99. "Update on HIV infections for the primary care provider"
Annual meeting of the Medical Society of Virginia, Norfolk, VA
October 30, 1992
100. "Outpatient management of patients with HIV infection"
Sponsored by Consortium for Physicians AIDS/HIV Education, Regional Conference Series, Four Seasons Hotel, Washington, DC
December 1, 1992
101. "Clinical infectious diseases"
Northern Virginia Microbiologists, Fairfax Hospital, Falls Church, VA
December 3, 1992
102. "Home care, office care and infusion centers"
Symposium on outpatient intravenous antibiotics Sonoma Mission Inn, Sonoma, CA
January 26, 1993
103. "Current status of HIV II"
Sexually Transmitted Diseases in the 90's
Northern Virginia Institute for Continuing Medical Education, Alexandria Hospital
Alexandria, VA
April 24, 1993
104. "Outpatient management of HIV"
The First Annual Advances in Clinical Practice of Infectious Diseases, Hyatt Regency, Washington, DC
August 26, 1993
105. "Outpatient management of serious infections"
The First Annual Advances in Clinical Practice of Infectious Diseases, Hyatt Regency, Washington, DC
August 26, 1993
106. "How to run an ID practice"
The First Annual Advances in Clinical Practice of Infectious Diseases, Hyatt Regency, Washington, DC
August 26, 1993

107. "Social issues of infectious diseases"
Panel member
SmithKline Beecham Pharmaceuticals Anti-infective Conference, Washington, DC
September 1-3, 1993
108. "Models for home treatment in the U.S.A."
Symposium - Home Treatment of Infectious Diseases with Parenteral
Antimicrobial Agents, Glaxo Auditorium, Utrecht, Netherlands
October 1, 1993
109. "Infusion devices"
Fairfax Hospital, Falls Church, VA
March 15, 1994
110. "HIV care and contracting"
OPIVITA, Chicago, IL
April 22, 1994
111. "The private practice of infectious diseases: past, present and future"
South Carolina Infectious Diseases Society (SCIDS), Keowee, SC
June 18, 1994
112. "Optimal management of herpesvirus infections"
Aspen, CO
August 26 and 27, 1994
113. "Experience with capitation for HIV disease care"
1994 IDAC (Infectious Disease Association of California)
Fall Symposium, Hollywood, CA
October 22, 1994
114. "Clinical trials in clinical practice"
Symposium sponsored by IDSA, US FDA, and Pharmaceutical Research and
Manufacturers of America, San Francisco, CA
September 15, 1995
115. "Skin and soft tissue infections"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
March 5, 1996
116. "Contracting For HIV patients" and "Managed Care in Infectious Diseases"
National conference sponsored by IDSA, SHEA, NFID, and OPIVITA, Chicago,
IL
June 21-22, 1996
117. "Inpatient antibiotic therapy"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA

August 13, 1996

118. "Nelfinavir clinical efficacy in HIV disease"
Address to Agouron Clinical Advisory Panel, McLean Hilton, Fairfax, VA
February 15, 1997
119. "Evolution of infectious disease practice"
Virginia Infectious Disease Society, Williamsburg, VA
March 22, 1997
120. "HIV update"
The 5th Annual OPIVITA Meeting, Phoenix, AZ
April 19, 1997
121. "Quinolones"
Medical Grand Rounds - Montgomery General Hospital, Olney, MD
May 8, 1997
122. "Nursing home infections"
Sponsored by University of Kentucky CME course, Tyson's Corner, VA
June 10, 1997
123. "Use of quinolones in the treatment of pneumonia"
Northern Virginia Society of Health-Systems Pharmacists, Fairfax, VA
June 17, 1997
124. "Combivir, a fixed formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI"
Poster session presented at 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL
February 4, 1998
125. "Advances in antibiotics with emphasis on quinolones"
Fauquier Hospital Medical Staff, Warrenton, VA
February 24, 1998
126. "Community-acquired pneumonia, bronchitis and sinusitis"
Frederick Memorial Hospital, Frederick, MD
March 11, 1998
127. "Outpatient and home parenteral antibiotic therapy (OHPAT)"
Chairman of Symposium at European Conference on Chemotherapy (ECC-2)
Hamburg, Germany
May 12, 1998
128. "Ritonavir (RTV)-saquinavir (SQV) in protease inhibitor-naïve patients after 72 weeks"

Donald M. Poretz, MD/24

Poster session presented at the 12th World AIDS Conference
Geneva, Switzerland
June 28, 1998 - July 3, 1998

129. "Community-acquired pneumonia"
S.E. Community Hospital, Washington, DC
November 18, 1998
130. "Acute coronary syndrome"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
January 26, 1999
131. "Rickettsial disease"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
May 4, 1999
132. "Hepatitis B"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
August 3, 1999
133. "New germ theory"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
October 12, 1999
134. "Outpatient treatment of infectious diseases"
Presented at ID 2000, Phoenix, AZ
October 28, 1999
135. Program Director of Northern Virginia Regional Resistance Roundtable
Presented at Department of Medicine, Inova Fairfax Hospital
Inova Institute of Research & Education, Falls Church, VA
November 1, 1999
136. "Bioterrorism"
Medical Grand Rounds - Fairfax Hospital, Falls Church, VA
November 16, 1999
137. "New germ theory"
Intra-City Infectious Diseases Grand Rounds, New Orleans, LA
December 3, 1999

Donald M. Poretz, MD/25

138. "New germ theory: are all diseases infectious?"
4th Halifax Medical Center Infectious Disease Conference, Daytona Beach, FL
May 6, 2000
139. "Respiratory infections with emphasis on gemifloxacin"
Workshop, Savannah, GA
August 12, 2000
140. "The impact on patient care and provider decision-making in a clinical setting"
Meeting to Better Understand and Avoid Antibiotic Shortages
Infectious Diseases Society of America, Arlington, VA
October 3, 2000
141. "Are all diseases infectious?"
Bayer Corporation
Infections in Emergency and Ambulatory Care
Mid-Atlantic Advisory Board, St. Michael's, MD
October 27, 2000
142. "Drug-resistant pneumococci in community hospitals"
FDA, Maryland
March 13, 2001
143. "Management of serious gram positive infections"
Meet the Experts IV: Selected Topics in Internal Medicine and Surgery
Inova Fairfax Hospital, Falls Church, VA
December 1, 2001
144. "Bioterrorism"
Presentation to reports and editors of *USA Today* - Tysons Corner, VA
December 13, 2001
145. "Resistant Gram-Positive Infections"
Eastern Virginia Medical School, Norfolk, VA
May 13, 2002
146. "Soft Tissue Infections"
Medical Grand Rounds, Inova Fairfax Hospital, Falls Church, VA
May 14, 2002

Research Activities:

1. Comparison of open (glass bottle) intravenous system vs closed (plastic bag) intravenous system. (1971-1972)
2. Evaluation of a new antibiotic, BRL-2333 (amoxicillin), 15 patients treated who had urinary tract infections. (1972)
3. Evaluation of a new parenteral cephalosporin antibiotic, cephacetrile, 15 patients evaluated. (1972-1973)
4. Correlation of NBT test and throat cultures in 90 patients with pharyngitis. (1973)
5. Studies involving outpatient self-administration of antibiotics. (1973-present)
6. Evaluation of cefazolin in urinary tract infections, 12 patients evaluated. (1975)
7. Evaluation of a new oral cephalosporin BL S-64OPG, double-blind study vs cephalexin. (1975)
8. Evaluation of cefamandole-tobramycin therapy in cases of presumed sepsis, 25 patients evaluated. (1977-1978)
9. Evaluation of intravenous amoxicillin. (1978-1979)
10. Evaluation of intravenous Bactrim in a variety of serious infections. (1979-1980)
11. Evaluation of LY127935, a new antibiotic. (1979-1980)
12. Evaluation of a new penicillin, piperacillin, in serious gram-negative infections. (1981)
13. Evaluation of a new cephalosporin, Rocephin. (1981-1983)
14. Comparative study of moxalactam and thienamycin in a variety serious infections. (1982-1983)
15. Usage of cefoperazone as a twice daily antibiotic given by self-administration via a heparin lock as an outpatient. (1983)
16. Evaluation of intravenous Timentin in urinary tract infections. (1983)
17. National cefoperazone cooperative study. (1983)
18. Evaluation of alpha-2 interferon in genital herpes infection. (1984)
19. Development of outpatient treatment programs for patients with AIDS. (1986-present)
20. Evaluation of parenteral cefotaxime sodium in infections caused by susceptible pathogens. (1989)

21. Evaluation of Claforan infusor in treatment of infections caused by susceptible pathogens. (1991)
22. Evaluation of fleroxacin vs ciprofloxacin for the treatment of community-acquired pneumonia. (1991)
23. Evaluation of azithromycin in respiratory tract infections. (1992)
24. Evaluation of gpl6O vaccine for HIV disease. (1992)
25. Evaluation of GM-CSF in leukopenic HIV positive individuals. (1994)
26. Evaluation of nevirapine in HIV positive individuals. (NVP1038A) (1994)
27. Evaluation of GM-CSF in neutropenic HIV positive individuals. (1994)
28. An open-label pilot evaluation of VALTREX for suppression of recurrent genital herpes in patients previously receiving continuous suppressive therapy with Zovirax. (Protocol #123-306) (1994)
29. Multicenter comparative study of Synercid versus standard therapy in the treatment of complicated gram-positive skin and skin structure infections. (JRV304) (1994)
30. The treatment of condyloma acuminata with interferon alfa-2b: the effect on the human papilloma virus. (1994)
31. 3TC open-label protocol NUCA 3004. Evaluation of 3TC in symptomatic HIV-diseased population who are unable to participate in all other approved therapies. (1995)
32. Treatment of infections due to vancomycin-resistant *Enterococcus faecium* (VREF) with Synercid (Quinupristin/Dalfopristin). (JRV301) (1995)
33. Open-label safety study of oral ganciclovir maintenance treatment of CMV retinitis in people with limited venous access. (GANS2224) (1995)
34. Open-label multicenter study to provide expanded access and to obtain additional safety data on Serostim (mammalian cell-derived recombinant human growth hormone) r-hGH[m] in the treatment of adults with advanced AIDS wasting. (Pr.7623) (1995)
35. A long-term open-label trial assessing safety and tolerance of chronic nevirapine dosing in HIV-1 infected patients. (NVPO1062A) (1995)
36. Double-blind comparative study of the efficacy and safety of orally administered OPC-17116 and clarithromycin in the treatment of patients with community-acquired pneumonia. (106-94-206) (1995)

37. The treatment of condyloma acuminata utilizing Roferon-A. (Protocol HLR-GW1) (1995)
38. A phase III safety and efficacy trial of ABT-538 plus current therapy vs placebo plus current therapy in HIV-infected patients. (M94-247) (1995)
39. Double-blind, vehicle-controlled study evaluating the safety of 5% topical Imiquimod cream for the treatment of external genital and perianal warts in HIV-positive patients. (1112-IMI) (1995)
40. A double-blind, randomized, placebo-controlled, multicenter, parallel-group study to investigate the efficacy and safety of ggl67 administered twice or four times a day for the treatment of influenza A and B viral infections. (NAIA/B2008) (1995)
41. A double-blind, randomized, placebo-controlled, multicenter, parallel-group study to investigate the efficacy and safety of ggl67 in the prevention and/or progression of influenza A and B viral infections. (NAIA/B2009) (1995)
42. The safety and efficacy of ritonavir in combination with saquinavir in HIV-infected patients. (1996)
43. A phase II study of intravenous Foscavir for the treatment of Kaposi's sarcoma. (1996)
44. A phase II trial to evaluate the safety and efficacy of recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) and amphotericin B versus amphotericin B alone in HIV-positive patients with oral candidiasis resistant or refractory to fluconazole. (1996)
45. A phase II trial to evaluate the safety and efficacy of recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) plus fluconazole versus fluconazole alone in HIV-positive patients with oral candidiasis resistant or refractory to fluconazole. (1996)
46. A randomized, double-blind, placebo-controlled 12-week clinical trial of topical 9-cis-retinoic acid gel (ALRT 1057) in the palliative treatment of cutaneous AIDS-related Kaposi's sarcoma. (1996)
47. A double-blind, randomized, placebo controlled study to evaluate the safety of SmithKline Beecham Biologicals' herpes Simplex Candidate Vaccine (gD2t) with MPL in HSV seropositive or seronegative subjects without genital herpes disease. (Protocol # 208141/016) (1996)
48. A multicenter, double-blind, phase III, adjuvant-controlled study of the effect of 10 units of HIV-1 Immunogen (REMUNE™) compared to IFA alone every 12 weeks on AIDS and HIV disease progression-free survival in subjects with HIV infection and CD4 T lymphocytes between 300 and 549 cells/ul regardless of concomitant HIV therapies. (Protocol #806) (1996)
49. An expanded access open label protocol of REMUNE™ in HIV-1 infected subjects. (Protocol #903) (1996)

50. A randomized, multicenter study of Efavir 150 mg BID, zidovudine 200 mg TID, and a protease inhibitor versus a 3TC 150 mg/ZDV 300 mg fixed-dose tablet given BID with a protease inhibitor in HIV-infected patients. (Protocol #NZTA4001). (1997)
51. A double-blind, randomized, placebo-controlled, parallel group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. (Protocol #NAIA3002) (1997)
52. A double-blind, randomized, placebo controlled study of GS 4104 (Ro 64-0796) for prophylaxis against human influenza virus. (Protocol #GS-97-804) (1997)
53. A randomized, double-blind, placebo-controlled evaluation of valaciclovir for the prevention of herpes simplex virus transmission in heterosexual couples. (Protocol #HS2AB3009) (1997)
54. A randomized phase IIIB comparative study to evaluate Saquinavir Soft Gel Capsule (SGC) TID regimen in combination with two NRTIs versus Saquinavir Soft Gel Capsule (SGC) BID regimen in combination with two NRTIs versus Saquinavir Soft Gel Capsule (SGC) BID plus nelfinavir BID plus a NRTI in HIV-1 Infected patients. (Protocol #NR15520B) (1997)
55. A phase III, double-blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of DMP 266 and indinavir versus indinavir in HIV-infected patients receiving nucleoside analogue (NRTI) therapy. (Protocol #DMP 266-020) (1997)
56. Open label Remune for HIV-infected subjects with CD4 counts ≤ 299 cells and ≥ 550 cells. (Protocol #IRC903) (1997)
57. A randomized open-label expanded access program to evaluate the safety of Preveon™ (adefovir dipivoxil) at two dose levels when used in combination with other antiretroviral agents for the treatment of patients with HIV infection who have limited treatment options. (Protocol #GS-97-423) (1998)
58. SUSTIVA™ (efavirenz) expanded access program. (Protocol #DMP-903) (1998)
59. Phase I/II study of ABT-378/Ritonavir in protease inhibitor experienced HIV-infected patients. (Protocol #M97-765) (1998)
60. An abacavir (1592U89) open label protocol for adult patients with HIV-1 infection- part B. (Protocol #CNAA3008) (1998)
61. A study of the safety and efficacy of low-dose interleukin-2 (IL-2) in combination with highly active antiretroviral therapy in patients with CD4+ T-cell counts less than 200 cells/mm³. (Protocol #MA9801) (1998)
62. A comparison of a four-drug regimen comprised of 141W94, abacavir (1592U89), and Combivir™ with a three-drug regimen comprised of nelfinavir and Combivir™ in antiretroviral-naïve, HIV-infected subjects. (Protocol #NZTA4002) (1998)

63. A randomized, multicenter, third party blinded trial comparing oral therapy of trovafloxacin vs. oral ciprofloxacin (Cipro™) (500 mg BID) plus clindamycin (Cleocin™) (300 mg QID) for the out-patient treatment of diabetic foot infections. (Protocol #R-0523) (1998)
64. Amprenavir (141W94) open-label for subjects with HIV-1 infection who have experienced treatment failure or are intolerant to previous protease inhibitor therapy. (Protocol #PRO30010) (1999)
65. An open-label, parallel group, pilot study of the safety, tolerance, pharmacokinetics and pharmacodynamics of BID and TID regimens of delavirdine mesylate, zidovudine, and indinavir sulfate in HIV-1 infected individuals. (Protocol #M/3331/0072) (1999)
66. A randomized, double-blind placebo-controlled, multi-center study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro64-0796 (also known as 654104). (Protocol #M76001) (1999)
67. Agenerase (amprenavir) expanded access program. Glaxo Wellcome (1999)
68. BID vs TID regimens of zidovudine, indinavir, and delavirdine in treatment-naïve, HIV-infected adults. Pharmacia & Upjohn (1999)
69. ABT/378/norvir and two nucleosides vs nelfinavir and two nucleosides in treatment-naïve, HIV-infected adults. Abbott Laboratories (1999)
70. Adefovir dipivoxil as intensification for HIV-infected adults with viral load of >50 and <400 on highly active antiretroviral therapy. Gilead Sciences (1999)
71. Efavirenz as replacement for protease inhibitor in highly active antiretroviral therapy, plus two nucleosides with viral load <50 for HIV-infected adults. Dupont Pharmaceuticals (1999)
72. Tipranavir/norvir plus efavirenz and one nucleoside in multiple protease inhibitor experienced, but NNRTI naïve HIV-infected adults with viral load >5,000 and CD4 >50. Pharmacia & Upjohn (1999)
73. Extension-1 of Proleukin (IL-2) for HIV-infected adults with CD4 cells <300 and viral load <500. Chiron Corporation (1999)
74. ABT-378/norvir plus nevirapine and two nucleoside analogues vs Principal Investigator selected protease inhibitor(s) plus nevirapine and two nucleoside analogues with viral load >1,000 in single protease inhibitor experienced, NNRTI naïve HIV-infected adults. Abbott Laboratories (1999)
75. Tipranavir/norvir plus two nucleoside analogues vs norvir plus saquinavir and two nucleoside analogues with viral load >5,000 and CD4 >50 in single protease inhibitor experienced HIV-infected adults. Pharmacia & Upjohn (1999)

Donald M. Poretz, MD/31

76. ABT-378/norvir Early Access Program for HIV-infected adults with limited treatment options. Abbott Laboratories (1999)
77. MK-0826 IV QD vs. Zosyn IV TID in complicated skin and skin structure infections. Merck Laboratories (1999)
78. The neuraminidase inhibitor, Tamiflu (Ro64-0796) vs placebo for the treatment of Influenza Type A and B. Roche Laboratories (1999)
79. Tenofovir vs. placebo for intensification of existing antiretroviral therapy. Gilead Sciences (2000)
80. ABT-378/ritonavir QD vs. BID in combination with stavudine and lamivudine in antiretroviral naïve patients. Abbott Laboratories (2000)
81. Tolerance and pharmacokinetics of various preparations of T-20 (HIV-1 infusion inhibitor) in treatment experienced HIV-infected adults. Trimeris, Inc. (2000)
82. HVTN 203. A phase II clinical trial to evaluate the immunogenicity and safety of a combined regimen using ALVAC VCP1452 and AIDSVAX B/B. (2000)
83. T20-210. A rollover study of T-20 administered in combination of a background antiviral regimen in HIV-1 positive adults who have completed clinical trial T1249-101 or T1249-102. (2000)
84. Protocol ESS40011. A 24-week randomized open-label, multicenter trial to compare the safety and efficacy of the licensed Agenerase dose (1200 mg BID) to a lower Agenerase dose (600 mg BID) in the presence of Norvir (100 mg BID) when combined with other background antiretroviral drugs in HIV-1 infected subjects. (2000)
85. Protocol A61549-509. A phase II, single-blind, randomized, placebo-controlled study of Capravirine (AG1549) in combination with Viracept and two nucleoside reverse transcriptase inhibitors in HIV-infected subjects who failed an initial nonnucleoside reverse transcriptase inhibitor containing regimen. (2000)
86. HVTN039. A phase I trial to evaluate the safety, tolerability, and immunogenicity of high dose live recombinant Canarypox ALVAC-HIV vaccine (VCP1452) in healthy, HIV-1 uninfected adult participants. (2001)
87. T1249-101. A phase I dose escalation trial to evaluate the safety, pharmacokinetics, and antiviral activity of T1249 in HIV-1 infected adults. (2001)
88. HVTN041. Phase I safety and immunogenicity trial of a combination vaccine (NefTat and gp120W61D) formulated with ASO2A (GlaxoSmithKline Biologicals) given intramuscularly in HIV-1 uninfected adult participants. (2002)
89. T1249-102. A phase I/II clinical trial to evaluate the safety and antiviral activity of T1249 in

Donald M. Poretz, MD/32

HIV-1 infected adults who have failed treatment with T-20 and background antiviral therapy and demonstrate reduced susceptibility to T-20. (2002)

**APPEARS THIS WAY
ON ORIGINAL**

Scientific Meetings Attended:

Infectious Disease Conference
Charlottesville, VA
1971

Medical Grand Rounds, Fairfax Hospital
Falls Church, VA
Weekly 1972 - present
Interscience Conference on Antimicrobial Agents and Chemotherapy
1972 - present

Infectious Diseases Society of America
1972 - present

26th ICAAC & 24th IDSA Annual Meeting
New Orleans, LA
October, 1986

27th ICAAC & 25th IDSA Annual Meeting
New York, NY
October, 1987

28th ICAAC & 26th IDSA Annual Meeting
Los Angeles, CA
October, 1988

29th ICAAC & 27th IDSA Annual Meeting
Houston, TX
September, 1989

30th ICAAC & 28th IDSA Annual Meeting
Atlanta, GA
October, 1990

31st ICAAC & 29th IDSA Annual Meeting
Chicago, IL
October, 1991

32nd ICAAC & 30th IDSA Annual Meeting
Anaheim, CA
October 1992

33rd ICAAC & 31st IDSA Annual Meeting
New Orleans, LA
October, 1993

Donald M. Poretz, MD/34

35th ICAAC & 33rd IDSA Annual Meeting
San Francisco, CA
September, 1995

36th ICAAC & 34th IDSA Annual Meeting
New Orleans, LA
September, 1996

37th ICAAC & 35th IDSA Annual Meeting
San Francisco, CA
September, 1997

36th IDSA Annual Meeting
Denver, CO
November, 1998

37th IDSA Annual Meeting
Philadelphia, PA
November, 1999

38th IDSA Annual Meeting
New Orleans, LA
September 7-10, 2000

39th IDSA Annual Meeting
San Francisco, CA
October 25-28, 2001

Conference on Gram Negative Septicemia, Johns Hopkins
Baltimore, MD
July 1973

Washington Inter-Institutional Infectious Disease Group
Monthly 1973 - present

Seminar on Infectious Diseases, Mt. Sinai Hospital
Miami, FL
January 1974

What's New in Pediatric Infectious Diseases?
Washington, DC
May 1974

Symposium on Kidney Disease, Shorham Hotel
Washington, DC
March 1975

Donald M. Poretz, MD/35

University of Virginia and Medical College of Virginia
Infectious Diseases combined meeting
Charlottesville, VA
Nov. 21, 1975

American College of Physicians Virginia Regional Meeting
February 1976

Infections of Prosthetic Valves and Vascular Grafts, Medical College of Virginia
Richmond, VA
Mar. 22-23, 1976

Current Concepts in Immunological Diseases: The American College of Physicians, Royal
Victoria Hospital
Montreal, CA
June 1-4, 1976

Interdisciplinary Symposium on the Care of the Critically Ill Patient, presented by Fairfax Hospital
George Mason University
Nov. 6, 1976
American College of Physicians Regional Meeting
Alexandria, VA
February 1977

2nd Interdisciplinary Symposium on the Care of the Critically Ill Patient, Fairfax Hospital
Falls Church, VA
Nov. 5, 1977

American College of Physicians Regional Meeting
Hot Springs, VA
Feb. 11-12, 1978

3rd Interdisciplinary Symposium on the Care of the Critically Ill Patient, Program Director,
Fairfax Hospital
Falls Church, VA
Nov. 18, 1978

American College of Physicians Regional Meeting
Norfolk, VA
Feb. 17, 1979

Cardiopulmonary Resuscitation Course, Fairfax Hospital
Falls Church, VA
Feb. 26, 1979

American Society of Internal Medicine, Alternate Delegate for VA

Donald M. Poretz, MD/36

New Orleans, LA
Apr. 26-29, 1979

4th Interdisciplinary Symposium on the Care of the Critically Ill Patient, Program Director,
Fairfax Hospital
George Mason University
Dec. 1, 1979

American College of Physicians Regional Meeting
Richmond, VA
February 1980

American College of Physicians Regional Meeting
New Orleans, LA
Feb. 11-12, 1980

5th Interdisciplinary Symposium on the Care of the Critically Ill Patient, Program Director,
Fairfax Hospital
Falls Church, VA
Nov. 22, 1980

American College of Physicians Regional Meeting
Hot Springs, VA
February 1981

12th International Conference on Chemotherapy
Florence, Italy
July 1981

6th Interdisciplinary Symposium on the Care of the Critically Ill Patient, Program Director,
Fairfax Hospital
Falls Church, VA
October 31, 1981

American College of Physicians Regional Meeting
Arlington, VA
Feb. 26-28, 1982

Hospital Conferences on Collaborative Practice
New York, NY
April 27, 1982

American Thoracic Society
Los Angeles, CA
May 17-18, 1982

Donald M. Poretz, MD/37

7th Interdisciplinary Symposium on the Care of the Critically Ill Patient, Program Director,
Fairfax Hospital
Falls Church, VA
November, 1982

American College of Physicians Regional Meeting
Williamsburg, VA
Feb. 18-20, 1983

International Congress of Chemotherapy
Vienna, Austria
Aug. 29-Sept. 2, 1983

9th Annual Critical Care Symposium on AIDS, Co-Director, Fairfax Hospital
Falls Church, VA
Nov. 18-19, 1983

American College of Physicians Regional Meeting
Hot Springs, VA
Feb. 24-26, 1984

Controversies in Infectious Diseases
Laguna Niguel, CA
Nov. 10-12, 1985

Ofloxacin Investigators' Meeting,
Phoenix, AZ
Nov. 17-19, 1988

47th Annual Scientific Meeting of the American Geriatrics Society and 11th Annual Scientific Meeting of the
American Federation for Aging Research
Atlanta, GA
May 17-20, 1990

State-of-the-Art Approaches to Managing HIV Infection, sponsored by Fairfax Hospital and
Northern Virginia HIV Resource and Consultation Center, Fairfax Hospital
Falls Church, VA
October 30, 1990

Quinolone Investigators' Meeting
Napa, CA
April 18-21, 1991

Controversies in Infectious Diseases, sponsored by College of Physicians and Surgeons
Tucson, AZ
Sept. 10-21, 1992

Donald M. Poretz, MD/38

OPIVITA National Education Conference
Chicago, IL
April 16-17, 1993

The First Annual Advances in Clinical Practice of Infectious Diseases, Hyatt Regency Washington
on Capitol Hill
Washington, DC
Aug. 26-28, 1993

OPIVITA National Education Conference
Chicago, IL
April 22-23, 1994

Controversies in Infectious Diseases, sponsored by SmithKline Beecham
New York, NY
Sept. 8-10, 1994

OPIVITA National Education Conference
Chicago, IL
April 20-22, 1995

Harold Neu Infectious Diseases Conference
Toronto, CA
Oct. 5-7, 1995

OPIVITA National Education Conference
Tucson, AZ
March 20, 1996

"The Diagnosis and Treatment of Onychomycosis." An interactive scientific meeting sponsored by Palazzole
Associates, Inc.
1996

4th Annual Conference on Outpatient Intravenous Infusion Therapy
Phoenix, AZ
Apr. 26-27, 1996

The 1996 Harold C. Neu Infectious Diseases Conference, SmithKline Beecham Pharmaceuticals
Anti-Infective Conference Controversies in Infectious Diseases
Washington, DC
Oct. 3-6, 1996

7th Annual State-of-the-Art Approaches to Managing HIV Infection, Sponsored by Fairfax Hospital and
Northern Virginia HIV Resources and Consultation Center, Fairfax Hospital
Falls Church, VA
Nov. 6, 1996

Donald M. Poretz, MD/39

Virginia Infectious Diseases Society Annual Conference
Williamsburg, VA
Mar. 21-23, 1997

OPIVITA V National Education Conference, The Pointe Hilton at Squaw Peak
Squaw Peak, AZ
Apr. 18-19, 1997

Harold Neu Infectious Diseases Conference
Chicago, IL
May 15-17, 1997

Second European Congress of Chemotherapy and 7th Biennial Conference on Anti-infective
Agents and Chemotherapy
Hamburg, Germany
May 10-13, 1998

Fourth Annual Daytona Beach Infectious Disease Conference
Halifax Medical Center
Daytona Beach, FL
May 6, 2000

**APPEARS THIS WAY
ON ORIGINAL**

Miscellaneous:

1. Review section on Communicable Diseases in Brunner and Suddarth Textbook of Medical Surgical Nursing, 2nd, 3rd, 4th, and 5th Editions
2. Director of Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital at George Mason University
November 6, 1976
3. Program and Planning Committee for American College of Physicians Regional Meeting,
Alexandria, VA
February 1977
4. Director of 2nd Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital
November 5, 1977
5. Program and Planning Committee for American College of Physicians Regional Meeting
Hot Springs, VA
February 11-12, 1978
6. Director of 3rd Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital
November 18, 1978
7. Director of 4th Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital
December 1, 1979
8. Director of 5th Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital
November 22, 1980
9. Development of an outpatient protocol for the treatment of patients requiring prolonged
course of antibiotics by using a heparin lock
1980 - present
10. Director of 6th Interdisciplinary Symposium on the Care of the Critically Ill Patient
Presented by Fairfax Hospital
October 31, 1981
11. Chairman of Program Committee, American College of Physicians Virginia Regional
Meeting
February 26-28, 1982
12. Co-director of Fairfax Hospital's 9th annual Critical Care Symposium on AIDS

Donald M. Poretz, MD/41

November 18-19, 1983

13. Review articles appearing in *Journal of the American Medical Association*, *New England Journal of Medicine*, *Annals of Internal Medicine*, *Archives of Internal Medicine*, *Pediatric Pulmonology*, *American Journal of Medicine*, *Infectious Diseases in Clinical Practice*, and *The Reviews of Infectious Diseases*.
14. Participation in Health Industry Manufacturer's Association study regarding outpatient intravenous antibiotics in Medicare population
15. HIVID Approved Faculty Speaker's Program
Roche Laboratories
1992
16. Reviewer for the Infectious Diseases Section, American Board of Internal Medicine
1994
17. Provide specimens for the National Cancer Institute HIV-Related Malignancy Bank
1995

(Updated June 2002)

APPEARS THIS WAY
ON ORIGINAL